Powder Containment & Aseptic Transfer Valve Systems - ChargePoint Technology is the market leader in powder containment and aseptic transfer valves providing operator safety and sterility assurance for the pharmaceutical, biotech, chemical and other process industries.
ChargePoint’s containment valves are independently tested to the ISPE SMEPAC guidelines for the transfer of powder, granular and other solid ingredients and small components within GMP manufacturing of cytotoxics, antibiotics and hormonal therapies to ensure the safe handling of a wide range of ingredients: Highly Potent Active Ingredients (HPAPI), Seed Intermediates, Tablets, Capsules.
Contained and sterile transfer solutions expert, ChargePoint Technology recently announces new, single use additions to its portfolio; the ChargePoint® Single Use Passive (SUP) and ChargeBag® PE-S with new HiPure ULP7 PE film.
ChargePoint Technology is the trusted sterile and contained transfer specialists, protecting your people, products and process with over a decade of expertise and knowledge.
Powder containment and sterile transfer solutions provider, ChargePoint Technology has achieved HazLoc (Hazardous Area) certification for VERIFI to further support customers in North America
Better containment in powder transfer helps to protect staff from exposure to APIs and HPAPIs, as well as improving efficiency, maintaining product quality and supporting compliance.
Better aseptic powder handling through the use of high-tech split butterfly valves can improve patient protection, improve working conditions for staffs and cut costs through the use of lower-grade cleanrooms.
Although pharmaceutical manufacturers take stringent steps to ensure that their production systems are as safe as possible, a fully gowned operator can still create as many 150,000 particles per minute, meaning that drug manufacturing is never a completely hazard-free process.
Which methods are most prominent in the pharmaceutical containment industry today and what key challenges are pharmaceutical businesses facing.
The global HPAPI market was valued at US$14.4 billion in 2016 and is expected to grow at a CAGR of 10.3 per cent, reaching US$34.8 billion by 2025.
Key considerations linked to containment performance testing, data collection methods and the interpretation of results.
Containment is key during aseptic processing and this has led to the development of new transfer methods that are both enclosed and minimize the requirement for operator intervention.
Powder containment and aseptic transfer valve specialist, ChargePoint Technology, has launched a unique Smart monitoring hub to support efficiency and safety within chemical and pharmaceutical manufacturing processes. The company will be exhibiting its new VERIFI solution at ACHEMA 2018, in Hall 3.0, stand D14.
Working towards a goal to define current good practices providing information to allow organizations to benchmark their practices and improve on them.
Manufacturers can benefit from this alternative transfer technology that has now been adapted to solve issues in aseptic handling.
Some 80 years after WWII, and the chemical compound used to propel V-2 rockets, is now being used in new technology that will help drug manufacturers ensure product quality and patient safety.
Powder containment and aseptic transfer valve specialist ChargePoint Technology is expanding its U.S. presence, following a multi-million-pound investment from LDC.
Powder containment and aseptic transfer valve specialist ChargePoint Technology has invested in new manufacturing machinery at its facility to meet increased demand for larger diameter valves for use in large scale drug manufacturing that requires containment.
Several techniques can be used to help ensure product sterility assurance during the transfer of pharmaceutical powders from one process stage to the next using an intermediate container.
As the pressures of modern living on the scientific, medical and technological sectors grows, maintaining the highest standards is more important than ever.
A pharma client needed to upgrade their facility to meet GMP requirements for closed handling of vial stopper components from an autoclave to a filling line.
Potent active pharma ingredients require ultra careful handling and containment. ChargePoint highlights the challenges and how they were effectively and safely dealt with for contract developer and manufacturer Fermion at Espoo.